IBAB Ion Beam Applications SA

IBA – ACQUISITION OF OWN SHARES

IBA – ACQUISITION OF OWN SHARES

Immediate Release – April 28th, 2025

Louvain-la-Neuve, Belgium, April 28th, 2025 - In accordance with article 8:4 of the Royal Decree of 29 April 2019 executing the Belgian Code on Companies and Associations, Ion Beam Applications SA (“IBA”) hereby discloses information in relation to its share buyback program announced on March 24th, 2025.

Under this program, IBA has requested a financial intermediary to repurchase up to 650,000 IBA ordinary shares on its behalf under the terms of a mandate with validity until December 31st, 2025, effective as from March 25th, 2025, to cover the company’s obligations under long-term incentive plans for management and certain members of its personnel.

In the framework of this share buyback program, IBA repurchased 122,000 IBA shares on Euronext Brussels in the period from April 22nd, 2025 up to and including April 28th, 2025, as follows:

        
 Trade dateShares purchasedAverage priceMin priceMax priceBuyback amount 
 22-04-2510,0009.70 €9.50 €9.98 €97,047.00 € 
 23-04-257,0009.96 €9.81 €10.06 €69,743.10 € 
 23-04-2585,0009.91 €9.91 €9.91 €842,350.00 € 
 24-04-258,00010.15 €9.95 €10.28 €81,224.00 € 
 25-04-256,00010.56 €10.42 €10.66 €63,334.80 € 
 28-04-256,00010.51 €10.46 €10.60 €63,060.60 € 
 TOTAL122,0009.97 €9.50 €10.66 €1,216,759.50 € 
        

These transactions include the purchase of a block of 85,000 shares at a price of 9.91 EUR/share, which was executed on April 23th, 2025 at 2:16:42 PM on the central order book of Euronext Brussels (XBRU).

The total number of shares purchased under this program therefore amounts to 474,017, following this fifth week of execution. As a result, the current situation with respect to treasury shares (held directly by IBA SA and indirectly through its subsidiary IBA Investments SRL) is the following :

  SharesVoting rights
IBA Investments SRL51,973103,946
IBA SA 787,596854,019
Total - Treasury shares839,569957,965
Total - Issued shares30,282,21840,514,366
Treasury shares in %2.77%2.36%

About IBA

IBA (Ion Beam Applications S.A.) is the world leader in particle accelerator technology. The company is the leading supplier of equipment and services in the fields of proton therapy, considered as the most advanced form of radiation therapy available today, as well as industrial sterilization, radiopharmaceuticals and dosimetry. The company, based in Louvain-la-Neuve, Belgium, employs approximately 2,100 people worldwide. IBA is a certified B Corporation (B Corp) meeting the highest standards of verified social and environmental performance.

IBA is listed on the pan-European stock exchange EURONEXT (IBA: Reuters IBAB.BR and Bloomberg IBAB.BB).

More information can be found at: -worldwide.com

Contact person

IBA

Thomas Pevenage

Investor Relations

Attachment



EN
28/04/2025

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Ion Beam Applications SA

ING Helpdesk
  • ING Helpdesk

Benelux Morning Notes

IBA: The Lancet Journal on proton therapy new standard of care for patients with Oropharyngeal cancer. Events Calendar

Hilde Van Boxstael ... (+7)
  • Hilde Van Boxstael
  • Jacob Mekhael
  • Livio Luyten
  • Michiel Declercq
  • Thomas Couvreur
  • Wim Hoste
  • Wim Lewi
 PRESS RELEASE

Proton Therapy New Standard of Care for Patients with Oropharyngeal Ca...

Proton Therapy New Standard of Care for Patients with Oropharyngeal Cancer Louvain-La-Neuve, Belgium, December 15, 2025 – (Ion Beam Applications S.A., EURONEXT), the world leader in particle accelerator technology and the world’s leading provider of proton therapy solutions for the treatment of cancer, is pleased to share today that, on December 11,  The Lancet – one of the world’s most renowned  academic journals – published a landmark study that recommends proton therapy as a new standard of care for patients with oropharyngeal cancer. , led by MD Anderson Cancer Center, the world’s ...

 PRESS RELEASE

La protonthérapie, nouvelle norme de soins pour les patients atteints ...

La protonthérapie, nouvelle norme de soins pour les patients atteints d'un cancer de l'oropharynx Louvain-la-Neuve, Belgique, le 15 décembre 2025 - IBA (Ion Beam Applications S.A., EURONEXT), le leader mondial des technologies d’accélération de particules et principal fournisseur de solutions de protonthérapie pour le traitement du cancer, a le plaisir d'annoncer aujourd'hui que The Lancet – l'une des revues scientifiques les plus renommées au monde – a publié, le 11 décembre, une étude historique recommandant la protonthérapie comme nouvelle norme de soins pour les patients atteints d'...

ING Helpdesk
  • ING Helpdesk

Benelux Morning Notes

Belgian Telecoms: DIGI Belgium CEO Interview: ‘We are running a marathon, not a sprint' IBA: IBA to install a Rhodotron in East China. Ontex: Another quarter, another profit warning. Theon International: Backlog visibility indeed. Xior: 2026 outlook positive but with no major surprise. Events Calendar

ResearchPool Subscriptions

Get the most out of your insights

Get in touch